Too many white cells—TAM, JMML, or something else?

2.

Lanzkowsky

P

,

Lipton

JM

,

Fish

JD

, eds.

Lanzkowsky’s manual of pediatric hematology and oncology (6th ed)

.

London

:

Academic Press

;

2016

.

3.

Hasle

H

,

Clemmensen

IH

,

Mikkelsen

M.

Risks of leukaemia and solid tumours in individuals with Down's syndrome

.

Lancet

.

2000

;

355

(

9199

):

165

-

169

.

doi:10.1016/s0140-6736(99)05264-2

.

4.

Marlow

EC

,

Ducore

J

,

Kwan

ML

, et al.

Leukemia risk in a cohort of 3.9 million children with and without Down Syndrome

.

J Pediatr

.

2021

;

234

(

suppl

):

172

-

180.e3180e3

.

doi:10.13039/100000054

.

5.

Khoury

JD

,

Solary

E

,

Abla

O

, et al.

The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms

.

Leukemia

.

2022

;

36

(

7

):

1703

-

1719

.

doi:10.1038/s41375-022-01613-1

.

6.

Wechsler

J

,

Greene

M

,

McDevitt

MA

, et al.

Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome

.

Nat Genet

.

2002

;

32

(

1

):

148

-

152

.

doi:10.1038/ng955

.

7.

Alford

KA

,

Reinhardt

K

,

Garnett

C

, et al;

International Myeloid Leukemia- Down Syndrome Study Group

.

Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia

.

Blood

.

2011

;

118

(

8

):

2222

-

2238

.

doi:10.1182/blood-2011-03-342774

.

8.

Roberts

I.

Leukemogenesis in infants and young children with trisomy 21

.

Hematology

.

2022

;

2022

(

1

):

1

-

8

.

doi:10.1182/hematology.2022000395

.

9.

Roberts

I

,

Alford

K

,

Hall

G

, et al;

Oxford-Imperial Down Syndrome Cohort Study Group

.

GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia

.

Blood

.

2013

;

122

(

24

):

3908

-

3917

.

doi:10.1182/blood-2013-07-515148

.

10.

Gamis

AS

,

Alonzo

TA

,

Gerbing

RB

, et al.

Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971

.

Blood

.

2011

;

118

(

26

):

6752

-

6759

; quiz 6996.

doi:10.1182/blood-2011-04-350017

.

11.

Massey

GV

,

Zipursky

A

,

Chang

MN

, et al;

Children's Oncology Group (COG)

.

A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481

.

Blood

.

2006

;

107

(

12

):

4606

-

4613

.

doi:10.1182/blood-2005-06-2448

.

12.

Brouwer

N

,

Matarraz

S

,

Nierkens

S

, et al.

Immunophenotypic analysis of acute megakaryoblastic leukemia: a EuroFlow Study

.

Cancers (Basel)

.

2022

;

14

(

6

).

doi:10.3390/cancers14061583

.

13.

Klusmann

J-H

,

Creutzig

U

,

Zimmermann

M

, et al.

Treatment and prognostic impact of transient leukemia in neonates with Down syndrome

.

Blood

.

2008

;

111

(

6

):

2991

-

2998

.

doi:10.1182/blood-2007-10-118810

.

14.

Tunstall

O

,

Bhatnagar

N

,

James

B

, et al;

British Society for Haematology

.

Guidelines for the investigation and management of transient leukaemia of Down Syndrome

.

Br J Haematol

.

2018

;

182

(

2

):

200

-

211

.

doi:10.1111/bjh.15390

.

15.

Flasinski

M

,

Scheibke

K

,

Zimmermann

M

, et al.

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 Study

.

Blood Adv

.

2018

;

2

(

13

):

1532

-

1540

.

doi:10.1182/bloodadvances.2018018945

.

16.

Yamato

G

,

Deguchi

T

,

Terui

K

, et al.

Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome

.

Leukemia

.

2021

;

35

(

5

):

1480

-

1484

.

doi:10.1038/s41375-021-01171-y

.

17.

Nikolaev

SI

,

Santoni

F

,

Vannier

A

, et al.

Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome

.

Blood

.

2013

;

122

(

4

):

554

-

561

.

doi:10.1182/blood-2013-03-491936

.

18.

Yoshida

K

,

Toki

T

,

Okuno

Y

, et al.

The landscape of somatic mutations in Down syndrome–related myeloid disorders

.

Nat Genet

.

2013

;

45

(

11

):

1293

-

1299

.

doi:10.1038/ng.2759

.

19.

Hitzler

JK

,

Zipursky

A.

Origins of leukaemia in children with Down syndrome

.

Nat Rev Cancer

.

2005

;

5

(

1

):

11

-

20

.

doi:10.1038/nrc1525

.

20.

Hasle

H

,

Abrahamsson

J

,

Arola

M

, et al.

Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML

.

Leukemia

.

2008

;

22

(

7

):

1428

-

1430

.

doi:10.1038/sj.leu.2405060

.

21.

Taub

JW

,

Berman

JN

,

Hitzler

JK

, et al.

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 Trial

.

Blood

.

2017

;

129

(

25

):

3304

-

3313

.

doi:10.1182/blood-2017-01-764324

.

22.

Hitzler

J

,

Alonzo

T

,

Gerbing

R

, et al.

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 Trial

.

Blood

.

2021

;

138

(

23

):

2337

-

2346

.

doi:10.1182/blood.2021012206

.

23.

Taga

T

,

Watanabe

T

,

Tomizawa

D

, et al.

Preserved high probability of overall survival with significant reduction of chemotherapy for myeloid leukemia in down syndrome: a nationwide prospective study in Japan: reduction of chemotherapy for AML with Down syndrome

.

Pediatr Blood Cancer

.

2016

;

63

(

2

):

248

-

254

.

doi:10.1002/pbc.25789

.

24.

Raghuram

N

,

Nakashima

K

,

Ab Rahman

S

, et al.

Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome

.

Blood Adv

.

2023

;bloodadvances.2022009381.

doi:10.1182/bloodadvances.2022009381

.

25.

Bertrums

EJM

,

Zwaan

CM

,

Hasegawa

D

, et al.

Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS

.

Haematologica

.

2022

;

107

(

3

):

759

-

764

.

doi:10.3324/haematol.2021.279507

.

26.

Huggard

D

,

Doherty

DG

,

Molloy

EJ

.

Immune dysregulation in children with Down syndrome

.

Front Pediatr

.

2020

;

8

:

73

.

doi:10.3389/fped.2020.00073

.

27.

Hertzberg

L

,

Vendramini

E

,

Ganmore

I

, et al.

Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group

.

Blood

.

2010

;

115

(

5

):

1006

-

1017

.

doi:10.1182/blood-2009-08-235408

.

28.

Buitenkamp

TD

,

Izraeli

S

,

Zimmermann

M

, et al.

Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group

.

Blood

.

2014

;

123

(

1

):

70

-

77

.

doi:10.1182/blood-2013-06-509463

.

29.

Arber

DA

,

Orazi

A

,

Hasserjian

R

, et al.

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

.

Blood

.

2016

;

127

(

20

):

2391

-

2405

.

doi:10.1182/blood-2016-03-643544

.

30.

Arber

DA

,

Orazi

A

,

Hasserjian

RP

, et al.

International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data

.

Blood

.

2022

;

140

(

11

):

1200

-

1228

.

doi:10.1182/blood.2022015850

.

31.

Niemeyer

CM

,

Arico

M

,

Basso

G

, et al.

Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)

.

Blood

.

1997

;

89

(

10

):

3534

-

3543

.

doi:10.1182/blood.2021014689

.

32.

Passmore

SJ

,

Chessells

JM

,

Kempski

H

,

Hann

IM

,

Brownbill

PA

,

Stiller

CA

.

Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival

.

Br J Haematol

.

2003

;

121

(

5

):

758

-

767

.

doi:10.1046/j.1365-2141.2003.04361.x

.

33.

Locatelli

F

,

Niemeyer

CM

.

How I treat juvenile myelomonocytic leukemia

.

Blood

.

2015

;

125

(

7

):

1083

-

1090

.

doi:10.1182/blood-2014-08-550483

.

34.

Loh

ML

.

Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia

.

Br J Haematol

.

2011

;

152

(

6

):

677

-

687

.

doi:10.1111/j.1365-2141.2010.08525.x

.

35.

Wintering

A

,

Dvorak

CC

,

Stieglitz

E

,

Loh

ML

.

Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment

.

Blood Adv

.

2021

;

5

(

22

):

4783

-

4793

.

doi:10.1182/bloodadvances.2021005117

.

36.

Duncavage

EJ

,

Bagg

A

,

Hasserjian

RP

, et al.

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

.

Blood

.

2022

;

140

(

21

):

2228

-

2247

.

doi:10.1182/blood.2022015853

.

37.

Chao

AK

,

Meyer

JA

,

Lee

AG

, et al.

Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing

.

Leukemia

.

2020

;

34

(

2

):

662

-

666

.

doi:10.1038/s41375-019-0549-y

.

38.

Schönung

M

,

Meyer

J

,

Nöllke

P

, et al.

International consensus definition of DNA methylation subgroups in juvenile myelomonocytic leukemia

.

Clin Cancer Res

.

2021

;

27

(

1

):

158

-

168

.

doi:10.1158/1078-0432.CCR-20-3184

.

39.

Pinkel

D.

Differentiating juvenile myelomonocytic leukemia from infectious disease

.

Blood

.

1998

;

91

(

1

):

365

-

367

.

doi:10.1182/blood.V91.1.365

.

40.

Karow

A

,

Baumann

I

,

Niemeyer

CM

.

Morphologic differential diagnosis of juvenile myelomonocytic leukemia–pitfalls apart from viral infection

.

J Pediatr Hematol Oncol

.

2009

;

31

(

5

):

380

.

doi:10.1097/MPH.0b013e31819ed260

.

41.

Behnert

A

,

Lee

AG

,

Young

EP

, et al.

NUP98-NSD1 Driven MDS/MPN in childhood masquerading as JMML

.

J Pediatr Hematol Oncol

.

2021

;

43

(

6

):

e808

-

e811

.

doi:10.1097/MPH.0000000000001913

.

42.

Coenen

EA

,

Zwaan

CM

,

Reinhardt

D

, et al.

Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group

.

Blood

.

2013

;

122

(

15

):

2704

-

2713

.

doi:10.1182/blood-2013-02-485524

.

43.

Pérez

B

,

Mechinaud

F

,

Galambrun

C

, et al.

Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia

.

J Med Genet

.

2010

;

47

(

10

):

686

-

691

.

doi:10.1136/jmg.2010.076836

.

44.

Martinelli

S

,

De Luca

A

,

Stellacci

E

, et al.

Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype

.

Am J Hum Genet

.

2010

;

87

(

2

):

250

-

257

.

doi:10.1016/j.ajhg.2010.06.015

.

45.

Hecht

A

,

Meyer

JA

,

Behnert

A

, et al.

Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia

.

Haematologica

.

2022

;

107

(

1

):

178

-

186

.

doi:10.3324/haematol.2020.270595

.